Products for Research Use Only

Leramistat

CAT: 0804-HY-156622-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-156622-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM) . Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease[1][2][3].
CAS Number
1642602-54-7
Product Name Alternative
HMC-C-01-A; MBS2320
UNSPSC
12352005
Hazard Statement
H302
Target
Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/leramistat.html
Purity
98.00
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N#CC1=C(C2=CC=C(C=C2)S(N[C@H]3CC[C@](O)(CC3)C)(=O)=O)C=CC(Cl)=C1
Molecular Formula
C20H21ClN2O3S
Molecular Weight
404.91
Precautions
H302
References & Citations
[1]Pokharel MD, et al. Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics. Redox Biol. 2024 Apr;70:103049. |[2]Preparation of 1-methyl-4-[ (4-phenylphenyl) sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4- (2-pyridyl) phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use. World Intellectual Property Organization, WO2020035560 A1 2020-02-20.|[3]Preparation of N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) benzenesulfonamides and their therapeutic use. World Intellectual Property Organization, WO2014207445 A1 2014-12-31.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products